Healthcare specialist SHS Capital acquires a majority stake in Ackermann Instrumente GmbH, with the goal of forming a leading MedTech group
|
Issuer: SHS Gesellschaft für Beteiligungsmanagement mbH
/ Key word(s): Private Equity/Investment
Rietheim-Weilheim / Tübingen, 8 July 2025 Healthcare investor SHS Capital has acquired a majority stake in Ackermann Instrumente GmbH. The investment aims to expand Ackermann’s core business and, through partnerships and acquisitions of additional companies, build a leading, globally positioned MedTech group. Ackermann Instrumente GmbH, headquartered near Tuttlingen, is a leading manufacturer of high-quality surgical instruments, with a focus on endoscopy, implantology, and general surgery. Its vertically integrated in-house production ensures high product quality, cost efficiency, and full control across the value chain. Thanks to its proven regulatory expertise and operational flexibility, Ackermann has established itself as a trusted partner for medical professionals and MedTech companies alike. Steady revenue growth and a diversified, expanding customer base make the company an attractive partner to capitalise on the global trend towards minimally invasive surgical procedures, particularly in emerging markets. SHS sees great potential in Ackermann’s scalable business model and its international growth strategy. In the coming years, Ackermann will further strengthen its core operations, expand market reach, and drive targeted innovation. In a European MedTech market that is increasingly consolidating and shaped by the requirements of the MDR and company successions, Ackermann, especially due to its strong global sales network, is an attractive platform for further partnerships and acquisitions. "SHS is the right partner for the company succession in the medical technology sector," says Rolf Ackermann, former majority shareholder of Ackermann Instrumente GmbH. "A trusted partner with deep industry expertise and a long-term approach – that’s what convinced us." "With SHS, we have the opportunity to position Ackermann as a platform for building a powerful MedTech group," says CEO Peter Grassl. "The combination of regulatory pressure from the MDR, growing internationalization potential, and possible economies of scale makes this step strategically sound for many companies." Dr. Cornelius Maas, Partner at SHS Capital, commented: “Ackermann is a hidden champion in German MedTech – precisely the type of company we seek to partner with. The team has built a highly profitable, internationally active business with a compelling value proposition for clinicians and industry partners alike. We look forward to supporting the next phase of growth, both organically and through targeted partnerships and acquisitions.”
About Ackermann Instrumente GmbH: For more than seven decades, the Ackermann Group has successfully continued to develop, manufacture and distribute premium solutions for a vast variety of surgical applications, primarily in the fields of open and minimally-invasive surgery, and also ligating and spinal implants. In addition to our strong brands, we stand behind an array of unique and highly sophisticated products as an OEM manufacturer and are proud of our global market leadership. True to our vision, INNOVATING TRADITION. It has always been our goal to provide our customers and healthcare professionals with industry-leading value proposition, through continuous innovation in our products and processes. We also believe that it is equally important not to lose sight of our roots, and to preserve the craftsmanship that has been perfected over generations as an established family business. This enables us to maintain a productive and sustainable home for our staff and improve clinical outcomes every single day in over 100 countries around the world. More information at: https://www.ackermannsurgical.com/
About SHS Capital: SHS Capital is a private equity provider founded in 1993 that invests in healthcare companies in Europe. The focus of the investments is on expansion financing, shareholder changes and succession situations. "Building European Healthcare Champions" is the investment philosophy according to which SHS finances and develops portfolio companies. The Tübingen-based investor takes both minority and majority stakes. The national and international investors in SHS funds include pension funds, funds of funds, foundations, family offices, strategic investors, entrepreneurs and the SHS management team. The equity or equity-like investment of the AIF is up to € 50 million. Volumes in excess of this can be realised with a network of co-investors. In its investment decisions, SHS attaches great importance to the consideration of ESG aspects and has therefore committed itself to the guidelines of the UN PRI. SHS is currently investing from its sixth fund, which was launched in 2022 and has a volume of ca. € 270 million. More information at: http://www.shs-capital.eu Are you interested in receiving regular updates about SHS? Subscribe to our Newsletter PR contact:
Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
